chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a physician concerning a female patient who was vaccinated with a dose of GARDASIL. After receiving the injection, the patient fainted. Medical attention was sought. Subsequently, the patient recovered. Additional information has been requested.
Vac. site warm, red, tender, with redness extending down arm almost to elbow.
This client presented and stated he needed his 2nd dose Pfizer. He was rushed and harried and the staff gave him his dose prior to checking the immunization registry. After the dose was given, it was found that the person received a Janssen vaccine on 7/10/2021.
About 1 minute after receiving vaccination, lips were numb (like receiving local dental anesthesia) and felt fat.  Initial BP 140/89  HR 100 @10:00am.  BP 193/93 HR 133 @10:15am.  Numbness and tingling resolved by 10:15am.  BP 163/79 HR 85  O2 98% @10:35am.  Patient clinically stable.  Patient released at 10:35am.
pt brought to ED via EMS with c/o SOB, hypoxia; acute on chronic renal failure; treated with dexamethasone, redesivir, barcitinib, plavix, heparin, antibiotics; intubated on 90% FiO2 with 10 of PEEP; pt's condition worsened; hypotensive shock; family decided to withdraw aggressive measures; comfort care; pt died in the hospital
Migraine, muscle spasms, heart palpitations, arm soreness. All set in swiftly within a 30 minute period, two and a half days after the vaccine was administered.
She has a grey raised scab looking bump at the injection site that still has not gone away after over a month.
Information was received from a physician, pt post vaccine experienced dizziness, shortness of breath, nausea and fatigue.
This case was reported by a consumer via call center representative and described the occurrence of fatigue in a 72-year-old female patient who received SHINGRIX for prophylaxis. On 22nd February 2019, the patient received the 1st dose of SHINGRIX. On 23rd February 2019, 1 days after receiving SHINGRIX, the patient experienced fatigue. SHINGRIX was continued with no change. On an unknown date, the outcome of the fatigue was recovered/resolved. It was unknown if the reporter considered the fatigue to be related to SHINGRIX. Additional details were provided as follows: This case was reported by the patient's friend. The patient was very fatigued on the following day after receiving 1st dose of SHINGRIX. No further details were provided.
Headaches starting around 8 hours after vaccination. Felt around top + front of head. Around 12 hours after vaccination, headaches became severe. Woke up confused, dazed.  Lasted 8+ hours. Relieved with Tylenol and ibuprofen.
Received flu shot about 11:00 am, by 4:00 pm, the same day, I started to get red raised hives on my arms & by 8:00 pm they were over my entire body. Itching began and the hives raised up and I felt feverous.
Arthritis of R 3rd PIP and MCP joints after the first dose that resolved by itself but recurrence one week after the second dose it got worse to a point that I could not open a jar or torque the scope. The R 2nd PIP and MCP also got involved. I started myself on a month of Advil and it slowly got better over several months.     After the third dose : migratory Arthritis of lower back, MCPs, PIPs, L IP, wrists, R ankle. Fatigue and brain fog. Three rounds of prednisone that helps but symptoms recur now being started on Enbrel.
This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (9 year old was administered expired monovalent Moderna vaccine for the first dose of his primary series), PRODUCT TEMPERATURE EXCURSION ISSUE (the vial undergo temperature excursion), PRODUCT STORAGE ERROR (The vial was removed from freezer which expired on 17-nov-2022 and was administered on 21-nov-2022) and NO ADVERSE EVENT (No adverse event) in a 9-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.       No concomitant medications were reported. The storage condition at the time of the excursion was frozen. The vial had undergone  temperature excursions. It was unknown whether the patient previously had a Covid-19 infection.   The vial size was 2.5 ml. No other adverse reactions were reported. No treatment medications were reported.
Patient states that a couple of minutes from receiving the vaccine she got a hot flash. About 10 minutes after the vaccine the patient states that her mouth and face started drooping on left side. She took a drink and it felt weird.
No additional AE reported; HCP reporting VAQTA, PEDVAXHIB, and ROTATEQ were administered after a temperature excursion. Caller stated she did not have the exact dates of administration nor the names of the patients involved. No additional information provided. No additional AE; This spontaneous report was received from a Health Care Professional and refers to a 2-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On 12-DEC-2022, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, in right thigh, lot #W023937, expiration date: 06-DEC-2023, administered intramuscularly for prophylaxis (strength was not provided).  The administered dose of the vaccine experienced a temperature excursion (product storage error) since 01-DEC-2022. The vaccine administered were stored at temperatures excursion of 47.9 Fahrenheit (storage in clinical practice) for 47 minutes. Digital data logger was involved.  No adverse event was reported.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2301USA001175: US-009507513-2301USA009088: US-009507513-2301USA009110: US-009507513-2301USA009112:
A day after receiving Pneumovax patient had pain in left arm up to collarbone. The next day she woke up with splotched or red areas on arm.
Diffuse urticaria across entire body, mild facial swelling approximately 24 hrs after injection.
I had myalgia right after the vaccination. The myalgia went away. I still had some fatigue, headaches, and a milder pain. I had blood work and it indicated that I had a low red blood cell count on 6/22/2022. I was told that if it dropped lower I would have to have a transfusion. I was prescribed a medication ferrous sulfate. My gynecologist did say that if I am on my menstrual cycle to take tranexamic acid.
This case was reported by a physician via call center representative and described the occurrence of injection site discomfort in a 66-year-old female patient who received SHINGRIX (batch number C523T, expiry date 4th July 2020). On 9th April 2018, the patient received the 1st dose of SHINGRIX. On 9th April 2018, immediately after receiving SHINGRIX, the patient experienced injection site discomfort. In April 2018, the patient experienced flu symptoms, nausea and fatigue. On 19th April 2018, the patient experienced maculopapular rash, erythematous rash and shingles. In April 2018, the outcome of the injection site discomfort, flu symptoms, nausea and fatigue were recovered/resolved. On an unknown date, the outcome of the maculopapular rash and erythematous rash were not recovered/not resolved and the outcome of the shingles was unknown. It was unknown if the reporter considered the injection site discomfort, maculopapular rash, erythematous rash, flu symptoms, nausea, fatigue and shingles to be related to SHINGRIX. Additional details were provided as follows: The patient was not on other medications and received no additional vaccines on the day of the SHINGRIX vaccine or four weeks prior. The patient received SHINGRIX vaccine in the left deltoid. The physician reported that the patient was administered the SHINGRIX vaccine at another location and she experienced a little site discomfort. A couple of days later, she had nausea and fatigue and then she got better. A few days later, she had nausea, fatigue with flu like symptoms and then she got better again. On 19th April 2018, the day of reporting, the patient was experiencing a rash that she described as a classic rash which is slightly maculopapular. No blisters were present but the rash was red. All of the patient's other symptoms have resolved except the rash and at the reporting time the patient was being treated for shingles currently. The physician claimed that she was currently not treating the patient with steroids to avoid reducing the efficacy of the vaccine. The placement of the rash was on the patient's left anterior chest wall on the left axilla and left back. She described the location as exactly T1 distribution. The physician had to disconnect the call to see a patient, therefore, no additional details were available.
Someone who got both shots and still got a bad case/ Suspected vaccination failure; Got a bad case; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine and the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient got both shots and still got a bad case. The reporter stated that Shingles vaccine doesn't always work, but still a good idea to get. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory confirmation were unknown at the time of reporting.
FEVER; SENSITIVITY TO LIGHT; This spontaneous report received from a consumer via a company representative concerned a 5 decade old male. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk expiry: UNKNOWN) dose was not reported, administered on 12-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 12-MAR-2021, the subject experienced fever. On 12-MAR-2021, the subject experienced sensitivity to light. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever and sensitivity to light was not reported. This report was non-serious.
Low grade fevers, headache, body aches about 12 hrs after shot given- Tylenol given around 4pm - symptoms improved
Patient incorrectly given the COVID-19 (Moderna pediatric age 6 to 11 NDC: 80777-275-05) instead of the COVID-19 Moderna updated booster 18+.
Tendonitis in both ears and intermittent hearing loss with both ears and water build-up with and without infections in both ears
Following vaccination, the patient had tingling sensations in his arms, not focused in any particular area. He does not remember which arm was vaccinated. 4 days post-vaccination he developed rash and pustules on shoulders, particularly on the left side of the trunk, on chest and back. On 12/07/09, he was diagnosed with shingles and put on medication. As of 1/19/10, he is still suffering from post-herpetic neuralgia and on medication. He has a history of chickenpox in childhood. No history of vaccine related adverse events. He is HIV positive.  Follow-up information received - RE: Missing information letter dated 1/28/2010. Unfortunately, this information is not available to us. When a report of symptoms suggesting a possible adverse event of interest is received, our team attempts to contact the reporting individual - provided that permission to contact has been granted. We have contacted this patient and he or she has aggreed to share his or her contact information with VAERS. E-mail and phone number provided.
DISCHARGE DIAGNOSES: Covid 19 Viral enteritis secondary to covid Hypertensive urgency Excessive alcohol intake Severe hypokalemia Paroxysmal Afib Hx of tachybrady syndrome CKD III HOSPITAL COURSE: Patient is a vaccinated and boosted 83-year-old female who presents to the hospital after intractable nausea and vomiting.  She was found to have COVID-19.  She did not experience any hypoxia so no steroids were started.  She underwent a CT scan of her abdomen and pelvis due to the excessive vomiting with severe hypokalemia at 2.8 and an elevated white blood cell count.  The CT did incidentally show thickening of the sigmoid colon and excessive diverticulosis without pericolic inflammation or stranding.  She was initially put on Zosyn but this was discontinued after 2 days with resolution of her leukocytosis.  The leukocytosis was likely demargination and the nausea/vomiting secondary to viral enteritis from covid.  She also had elevation of her high-sensitivity troponin to a peak of 339.  EKG showed first-degree AV block with no ST changes.  It was likely that this was demand ischemia.  She is on amiodarone for A. fib.  Her blood pressure was elevated in hypertensive urgency.  She takes torsemide 20 mg daily, lisinopril 5 mg twice daily and amiodarone 200 mg daily at home.  Her blood pressure with these meds on board vacillated from the 120s to the 170s.  She reports that she gets anxious in doctors offices and hospitals and that that is likely why it is high.  She reports that she takes her blood pressure at home and it runs in the 120s systolic.  For this reason no additional medication was given.  She was instructed however to continue taking her blood pressure twice a day and if her blood pressure was over 160 systolic, she should take an extra 5 mg tablet of lisinopril.  She is to bring the log of her blood pressures to her PCP appointment.  Patient symptoms of nausea and vomiting resolved allowing her to take all of her oral medications, eat and drink.  It was noted that the patient had been told during her cardiology appointment as an outpatient to discuss changing her tizanidine with her PCP as it should not be used with amiodarone.  Flexeril was prescribed for a 1 month trial in its stead.  Patient can follow-up with PCP to determine if they want to continue this.  Patient is to remain in isolation for 5 full days and then can wear an N95 mask for the next 5 days when she is in contact with people.
widespread upper body papular rash within 12 hours of shot -- affecting face, neck, torso, back, upper extremities and palms
Adminstered vaccine past expiration date. Moderna confirmed vaccine was still viable at the time of administration.
Pt developed swelling at site of vaccine injection on right arm and swelling on left arm found to have a left brachial vein DVT.
swollen and sensitive at injection site day of and following. Nothing until following week where injection site is not hot, swollen and itchy
This is a spontaneous case, reported by other non-health professional (consumer) on 05-Nov-2018, concerning a female patient of unspecified age. On an unspecified date in 2017, the patient experienced little bit tired with body aches due to the FLUCELVAX vaccine. The patient's current condition included egg allergy. On an unspecified date in Oct-2018, the patient was administered FLUCELVAX QIVc [dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number and expiry date: not reported]. On an unspecified date in Oct-2018, the patient had recovered from the events (reported as lasted only for 1 day). The reporter assessed this case as non-serious. Non-significant follow-up from the reporter on 27-Nov-2018: No additional information was available in the source document, hence no changes were made in narrative.
Information has been received on 12-MAR-2019 from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 26-SEP-2007, the patient was administered the ZOSTAVAX vaccine (lot # and route not specified) by a physician. On an unspecified date, the patient was treated by a healthcare provider for shingles as a result of vaccination with ZOSTAVAX. The outcome was not provided. Additional information has been requested.
Had blindness in left eye and numbness in hand. Went to ER, diagnosis was lacunar stroke, received TPA, blood thinners
I had the shot/ Suspected Vaccination Failure; also got shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: I had the shot/ Suspected Vaccination Failure) (serious criteria GSK medically significant) and shingles (Verbatim: also got shingles). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 14-Mar-2023 This case was reported by a patient via interactive digital media. The patient had the shot and also got shingles. This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. Follow-up was not possible, as no contact details were available.
Patient developed generalized weakness 2 wks after the vaccines. It developed into TIP and encephalitis within 3 weeks. Currently pt is non verbal, moaning, not following commands. (+) myoclonus worse with stimulus.
Small itchy spots; This case was reported by a consumer and described the occurrence of pruritus in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 16th October 2022, the patient received the 1st dose of Shingles vaccine. On an unknown date, less than 3 weeks after receiving Shingles vaccine, the patient experienced pruritus. On an unknown date, the outcome of the pruritus was not recovered/not resolved.   It was unknown if the reporter considered the pruritus to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 05-Nov-2022 Reporter's Comments: The patient self-reported this case. The patient received the 1st shot of Shingles and had small itchy spots on his/her torso and wanted to know how alarmed should he/she be.
Patient presented in our office with c/o vaccine reaction to H1N1. Injection site swollen, itchy and erythematous. Mom reports symptoms resolved by 12/6/09.
Half inch tube shape cylinder swelling reaction below surface of skin, approximately 1-1/2 below injection site.
Pt states he has light headedness.  He was given water and wet paper towel was placed on his frontal.  Denies any known allergy.  BP 109/71, HR 60, RR 20. Patient stable and released from the vaccination site.
period came on 2 weeks early and very heavy; period came on 2 weeks early and very heavy; patient is crying a lot; moody; anxious; nervous; sad; Pain; chills; low grade fever; muscle aches; nauseous; This spontaneous case was reported by a patient and describes the occurrence of MENORRHAGIA (period came on 2 weeks early and very heavy), POLYMENORRHOEA (period came on 2 weeks early and very heavy), CRYING (patient is crying a lot), MOOD ALTERED (moody) and ANXIETY (anxious) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 15-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MENORRHAGIA (period came on 2 weeks early and very heavy), POLYMENORRHOEA (period came on 2 weeks early and very heavy), CRYING (patient is crying a lot), MOOD ALTERED (moody), ANXIETY (anxious), NERVOUSNESS (nervous), DEPRESSED MOOD (sad), PAIN (Pain), CHILLS (chills), PYREXIA (low grade fever), MYALGIA (muscle aches) and NAUSEA (nauseous). At the time of the report, MENORRHAGIA (period came on 2 weeks early and very heavy), POLYMENORRHOEA (period came on 2 weeks early and very heavy), CRYING (patient is crying a lot), MOOD ALTERED (moody), ANXIETY (anxious), NERVOUSNESS (nervous), DEPRESSED MOOD (sad), PAIN (Pain), CHILLS (chills), PYREXIA (low grade fever), MYALGIA (muscle aches) and NAUSEA (nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications and treatment information were not provided.
Severe nausea and vomiting for an entire day.  Could not keep any fluids down. Severe burning pain in muscles all throughout the body for 3 days. Severe muscle spasms and cramps all throughout the body.  Could not stand or walk for 12 hours. Severe burning sensation on the skin all over the body, felt like a sunburn. Severe headache for 3 days. Minor muscle spasms for an additional 5 days after the severe ones diminished. Moderate fatigue for 10 days.  Had tested positive for COVID 4 months prior to being vaccinated, but only had minor symptoms for 2 days.
hot flushed face; This spontaneous case was reported by a consumer and describes the occurrence of HOT FLUSH (hot flushed face) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 23-Jan-2021, the patient experienced HOT FLUSH (hot flushed face).            Reporter did not allow further contact